InvestorsHub Logo
Followers 19
Posts 1039
Boards Moderated 0
Alias Born 04/18/2018

Re: None

Saturday, 06/26/2021 1:08:13 PM

Saturday, June 26, 2021 1:08:13 PM

Post# of 35961
Immunotherapy is a hot item in biotechs and NSPX and Hislop must think that RT-AR001 has a more direct path to revenue than mipsagargin. All the effort lately is to get RT-AR001 approval for trials. However, mipsagargin has orphan status until 2034 so mipsagargin’s thapsigargin based drug platform is not going away and will eventually have it’s day!